Therapeutic Asset Ratings

188 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
VEMURAFENIB Colorectal Neoplasm	Cancer Research UK	P2/3	CCC (51)
VEMURAFENIB Ovarian Neoplasm	Cancer Research UK	P2/3	CCC (51)
ALECTINIB Lymphoma	Cancer Research UK	P2/3	CCC (50)
ALECTINIB Renal Cell Carcinoma	Cancer Research UK	P2/3	CCC (50)
Capmatinib Cancer	Cancer Research UK	P2/3	CCC (50)
Capmatinib Hematopoietic And Lymphoid System Neoplasm	Cancer Research UK	P2/3	CCC (50)
Capmatinib Neuroblastoma	Cancer Research UK	P2/3	CCC (50)
Capmatinib Soft Tissue Sarcoma	Cancer Research UK	P2/3	CCC (50)
Capmatinib Solid Tumour	Cancer Research UK	P2/3	CCC (50)
Atezolizumab Pheochromocytoma	Cancer Research UK	P1/2	CCC (48)
Atezolizumab Urinary Bladder Neoplasm	Cancer Research UK	P1/2	CCC (48)
Capmatinib Cancer	Cancer Research UK	P2/3	CCC (48)
Capmatinib Glioma	Cancer Research UK	P2/3	CCC (48)
Chadox1-Magea3-Nyeso Esophageal Squamous Cell Carcinoma	Cancer Research UK	P1/2	CCC (48)
Enzalutamide Esophageal Cancer	Cancer Research UK	P1/2	CCC (48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-3101 (89.9%) -(IGHD) -IGHJ401 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG101 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (85.3%)-IGKJ201 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa Esophageal Cancer	Cancer Research UK	P1/2	CCC (48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-3101 (89.9%) -(IGHD) -IGHJ401 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG101 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (85.3%)-IGKJ201 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa Colorectal Cancer	Cancer Research UK	P1/2	CCC (48)
htl0039732 capsules Pheochromocytoma	Cancer Research UK	P1/2	CCC (48)
htl0039732 capsules Urinary Bladder Neoplasm	Cancer Research UK	P1/2	CCC (48)
Mva-Magea3 Esophageal Squamous Cell Carcinoma	Cancer Research UK	P1/2	CCC (48)
Mva-Nyeso Esophageal Squamous Cell Carcinoma	Cancer Research UK	P1/2	CCC (48)
Aleta-001 Follicular Lymphoma	Cancer Research UK	P1/2	CC (47)
Aleta-001 Mantle Cell Lymphoma	Cancer Research UK	P1/2	CC (47)
egf816 Haematological Malignancy	Cancer Research UK	P2/3	CC (47)
egf816 Neoplasms by Histologic Type	Cancer Research UK	P2/3	CC (47)

Showing 101 to 125 of 188 assets

PreviousPage 5 of 8Next